Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBITDA (2019 - 2025)

Historic EBITDA for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.4 million.

  • Eton Pharmaceuticals' EBITDA fell 36778.0% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 4866.83%. This contributed to the annual value of -$2.6 million for FY2024, which is 11786.91% down from last year.
  • Per Eton Pharmaceuticals' latest filing, its EBITDA stood at -$1.4 million for Q3 2025, which was down 36778.0% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' EBITDA registered a high of $5.4 million during Q1 2021, and its lowest value of -$5.8 million during Q3 2021.
  • Its 5-year average for EBITDA is -$886947.4, with a median of -$1.3 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 38977.61% in 2023, then plummeted by 36778.0% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA (Quarter) stood at $1.3 million in 2021, then dropped by 19.18% to $1.1 million in 2022, then plummeted by 287.66% to -$2.0 million in 2023, then surged by 131.56% to $629000.0 in 2024, then plummeted by 316.69% to -$1.4 million in 2025.
  • Its EBITDA stands at -$1.4 million for Q3 2025, versus -$1.5 million for Q2 2025 and -$470000.0 for Q1 2025.